AL HJR162

Alabama Medicaid Agency is encouraged to evaluate potential savings from covering GLP-1 weight management medications, considering new federal drug pricing models expected to be announced by Spring 2026

Approximately 110,000 adult and child Medicaid members in Alabama may qualify for GLP-1 medications for weight management under current FDA labeling

Obesity affects 38.9% of Alabama adults and 15.6% of children in the WIC program, costing the state an estimated $7.2 billion in GDP impact and over $750 million annually in budget expenditures

The agency is directed to consult with healthcare providers and stakeholders to assess health outcomes and cost savings if coverage is implemented

Findings must be reported to the Legislature prior to the 2027 Legislative Session